9704 MEDICAL CENTER DRIVE, Rockville, MD
Amended material disclosure
Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
Provides Clinical Update on Ongoing Phase 1 Study for MGC026
Director Resignation - Karen Ferrante Steps Down from Board
Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
MacroGenics, Inc. Annual Meeting - Stockholder Votes on Director Elections
Reports First Quarter 2026 Financial Results and Highlights Business Transformation
To Sell GMP Manufacturing Operations to Pharmaceuticals
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report